FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
News|Articles|October 24, 2019
Pfizer Recalls Batches of Docetaxel Injection
Author(s)Pharmaceutical Technology Editors
Pfizer has issued a voluntary recall of batches of its docetaxel injection 80 mg/8 mL due to impurity concerns.
Advertisement
According to an announcement by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) on Oct. 22, 2019, Pfizer has issued a voluntary recall of batches of its docetaxel injection 80 mg/8 mL due to impurity concerns.
The specific batches to be recalled are S0130118 and S0140518, as specified on MHRA’s website. Pfizer’s reasoning for the recall is that during routine stability testing, impurity, 10-oxo-docetaxel, was identified at potentially unacceptable levels towards the end of the product’s shelf-life.
This latest recall follows from the company’s earlier recall of batches of docetaxel injection 160 mg/16 mL and docetaxel injection 20 mg/2 mL in June 2019. The earlier recall was also a result of potentially unacceptable levels of 10-oxo-docetaxel at the end of shelf-life.
Source:
Advertisement
Related to this article
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
FDA final guidance defines when companion app output counts as drug labeling and when device-connected or standalone apps belong in prescribing information.
Boyang Wang of Immortal Dragons explains how FDA's Expedited IND Pilot and QRIs could compress sequential first-in-human steps as China's Decree 818 raises the pace.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Jaenisch, Muraru, and Pandey discuss new skills for QC and regulatory teams, plus patient trust, as new approach methodologies reshape pharma.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
2
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
3
Nitrosamine Problems and Industry Solutions: PharmTech Explained
4
FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note
5